Immunic financials
$8.91−6.31%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Quarter | Q2 '26 Jun 30 | Q1 '26 Mar 31 | Q4 '25 Dec 31 | Q3 '25 Sep 30 | Q2 '25 Jun 30 | Q1 '25 Mar 31 | Q4 '24 Dec 31 | Q3 '24 Sep 30 | Q2 '24 Jun 30 | Q1 '24 Mar 31 | Q4 '23 Dec 31 | Q3 '23 Sep 30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | -$35.3M | -$33.2M | -$23.3M | -$26.0M | -$27.1M | -$26.8M | -$25.6M | -$25.7M | -$22.8M | -$23.9M | -$23.4M | -$23.6M |
| Net income | -$34.1M | -$32.6M | -$19.3M | -$25.6M | -$26.8M | -$25.5M | -$25.2M | -$24.4M | -$21.4M | -$29.6M | -$21.6M | -$22.8M |
| Net margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Diluted EPS | $-0.80 | $-1.08 | $-0.48 | $-1.30 | $-2.03 | $-2.51 | $-2.50 | $-2.40 | $-2.10 | $-3.00 | $-4.84 | $-5.10 |
| EBITDA | -$35.3M | -$33.2M | -$23.3M | -$26.0M | -$27.0M | -$26.8M | -$25.6M | -$25.7M | -$22.8M | -$23.9M | -$23.4M | -$23.5M |
| Operating cash flow | -$31.0M | -$17.3M | -$19.3M | -$20.1M | -$24.6M | -$21.8M | -$23.0M | -$20.8M | -$17.0M | -$24.0M | -$14.0M | -$17.3M |
| Free cash flow | -$31.2M | -$17.3M | -$19.3M | -$20.2M | -$24.6M | -$21.8M | -$23.0M | -$20.8M | -$17.2M | -$24.0M | -$14.2M | -$17.4M |
| Diluted shares | 42.5M | 30.1M | 40.6M | 19.4M | 13.2M | 10.1M | 10.1M | 10.1M | 10.1M | 9.7M | 4.5M | 4.5M |
Balance sheet
| Period end | Jun 30 | Mar 31 | Dec 31 | Sep 30 | Jun 30 | Mar 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $155.1M | $186.6M | $15.5M | $35.1M | $55.3M | $14.3M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $159.2M | $189.7M | $24.1M | $40.7M | $61.4M | $20.5M |
| Total liabilities | $31.6M | $38.5M | $30.7M | $30.2M | $27.5M | $25.8M |
| Shareholders' equity | $127.6M | $151.2M | -$6.7M | $10.5M | $33.9M | -$5.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology